Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
Immune-related adverse events (irAEs) are frequent and could be associated with improved response to immune checkpoint inhibitors (ICIs). A prospective cohort of advanced melanoma patients receiving ICI as first-line therapy was retrospectively reviewed (January 2011–February 2019). A total of 116 o...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/5/1237 |
| _version_ | 1797475479555407872 |
|---|---|
| author | Lorena Villa-Crespo Sebastian Podlipnik Natalia Anglada Clara Izquierdo Priscila Giavedoni Pablo Iglesias Mireia Dominguez Francisco Aya Ana Arance Josep Malvehy Susana Puig Cristina Carrera |
| author_facet | Lorena Villa-Crespo Sebastian Podlipnik Natalia Anglada Clara Izquierdo Priscila Giavedoni Pablo Iglesias Mireia Dominguez Francisco Aya Ana Arance Josep Malvehy Susana Puig Cristina Carrera |
| author_sort | Lorena Villa-Crespo |
| collection | DOAJ |
| description | Immune-related adverse events (irAEs) are frequent and could be associated with improved response to immune checkpoint inhibitors (ICIs). A prospective cohort of advanced melanoma patients receiving ICI as first-line therapy was retrospectively reviewed (January 2011–February 2019). A total of 116 of 153 patients presented with at least one irAE (75.8%). The most frequent irAEs were dermatological (derm irAEs, 50%), asthenia (38%), and gastrointestinal (29%). Most irAEs appeared within the first 90 days, while 11.2% appeared after discontinuation of the therapy. Mild grade 1–2 derm irAEs tended to appear within the first 2 months of therapy with a median time of 65.5 days (IQR 26-139.25), while grade 3–4 derm irAEs appeared later (median 114 days; IQR 69-218) and could be detected at any time during therapy. Only derm irAE occurrence was related to improved survival (HR 6.46). Patients presenting derm irAEs showed better 5-year overall survival compared to those with no derm irAEs (53.1% versus 24.9%; <i>p</i> < 0.001). However, the difference was not significant when adjusting for the duration of therapy. In conclusion: the timeline of immune-related-AEs differs according to the organ involved. The (apparent) improved survival of patients who present derm AEs during immunotherapy could be partially explained by longer times under treatment. |
| first_indexed | 2024-03-09T20:45:42Z |
| format | Article |
| id | doaj.art-6e967ae1ee6b48b3811a781a497f1aa7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:45:42Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6e967ae1ee6b48b3811a781a497f1aa72023-11-23T22:47:56ZengMDPI AGCancers2072-66942022-02-01145123710.3390/cancers14051237Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on SurvivalLorena Villa-Crespo0Sebastian Podlipnik1Natalia Anglada2Clara Izquierdo3Priscila Giavedoni4Pablo Iglesias5Mireia Dominguez6Francisco Aya7Ana Arance8Josep Malvehy9Susana Puig10Cristina Carrera11Melanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMedicine Department, Medicine Faculty, Campus Clínic, University of Barcelona, 08036 Barcelona, SpainMedicine Department, Medicine Faculty, Campus Clínic, University of Barcelona, 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMedical Oncology Department, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, SpainMedical Oncology Department, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainMelanoma Group, Institut d’Investigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainImmune-related adverse events (irAEs) are frequent and could be associated with improved response to immune checkpoint inhibitors (ICIs). A prospective cohort of advanced melanoma patients receiving ICI as first-line therapy was retrospectively reviewed (January 2011–February 2019). A total of 116 of 153 patients presented with at least one irAE (75.8%). The most frequent irAEs were dermatological (derm irAEs, 50%), asthenia (38%), and gastrointestinal (29%). Most irAEs appeared within the first 90 days, while 11.2% appeared after discontinuation of the therapy. Mild grade 1–2 derm irAEs tended to appear within the first 2 months of therapy with a median time of 65.5 days (IQR 26-139.25), while grade 3–4 derm irAEs appeared later (median 114 days; IQR 69-218) and could be detected at any time during therapy. Only derm irAE occurrence was related to improved survival (HR 6.46). Patients presenting derm irAEs showed better 5-year overall survival compared to those with no derm irAEs (53.1% versus 24.9%; <i>p</i> < 0.001). However, the difference was not significant when adjusting for the duration of therapy. In conclusion: the timeline of immune-related-AEs differs according to the organ involved. The (apparent) improved survival of patients who present derm AEs during immunotherapy could be partially explained by longer times under treatment.https://www.mdpi.com/2072-6694/14/5/1237immunotherapymelanomadermatological adverse eventsimmune-related adverse eventsimmune checkpoint inhibitorsdermatological drug reactions |
| spellingShingle | Lorena Villa-Crespo Sebastian Podlipnik Natalia Anglada Clara Izquierdo Priscila Giavedoni Pablo Iglesias Mireia Dominguez Francisco Aya Ana Arance Josep Malvehy Susana Puig Cristina Carrera Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival Cancers immunotherapy melanoma dermatological adverse events immune-related adverse events immune checkpoint inhibitors dermatological drug reactions |
| title | Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival |
| title_full | Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival |
| title_fullStr | Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival |
| title_full_unstemmed | Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival |
| title_short | Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival |
| title_sort | timeline of adverse events during immune checkpoint inhibitors for advanced melanoma and their impacts on survival |
| topic | immunotherapy melanoma dermatological adverse events immune-related adverse events immune checkpoint inhibitors dermatological drug reactions |
| url | https://www.mdpi.com/2072-6694/14/5/1237 |
| work_keys_str_mv | AT lorenavillacrespo timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT sebastianpodlipnik timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT nataliaanglada timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT claraizquierdo timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT priscilagiavedoni timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT pabloiglesias timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT mireiadominguez timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT franciscoaya timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT anaarance timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT josepmalvehy timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT susanapuig timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival AT cristinacarrera timelineofadverseeventsduringimmunecheckpointinhibitorsforadvancedmelanomaandtheirimpactsonsurvival |